A Pilot of Emergency Department-Initiated Buprenorphine for  Opioid Withdrawal and Opioid Use Disorder: A Quality Improvement Project by Lucey, Jason
University of New Hampshire
University of New Hampshire Scholars' Repository
DNP Scholarly Projects Student Scholarship
Spring 2019
A Pilot of Emergency Department-Initiated
Buprenorphine for Opioid Withdrawal and Opioid
Use Disorder: A Quality Improvement Project
Jason Lucey
Follow this and additional works at: https://scholars.unh.edu/scholarly_projects
Part of the Health and Medical Administration Commons, Nursing Commons, and the
Substance Abuse and Addiction Commons
This Clinical Doctorate is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository. It
has been accepted for inclusion in DNP Scholarly Projects by an authorized administrator of University of New Hampshire Scholars' Repository. For
more information, please contact nicole.hentz@unh.edu.
Recommended Citation
Lucey, Jason, "A Pilot of Emergency Department-Initiated Buprenorphine for Opioid Withdrawal and Opioid Use Disorder: A Quality
Improvement Project" (2019). DNP Scholarly Projects. 18.
https://scholars.unh.edu/scholarly_projects/18













A Pilot of Emergency Department-Initiated Buprenorphine for  
Opioid Withdrawal and Opioid Use Disorder: A Quality Improvement Project 
Jason R. Lucey 
University of New Hampshire  










Faculty Mentor:  Kerry Nolte, PhD, FNP-C 
Practice Mentor:  Kellie Mueller, MEd 
Date of Submission: May 13, 2019 
ED-INITIATED BUPRENORPHINE  2  
 
Table of Contents 
Reported using SQUIRE 2.0 Guidelines (Ogrinc et al., 2015) 
Abstract ................................................................................................................................4 
Introduction ..........................................................................................................................5 
      Problem Description ......................................................................................................5 
      Available knowledge .....................................................................................................6  
           The Opioid Epidemic and Emergency Departments ................................................6 
           Pharmacotherapy for OUD .......................................................................................6 
           Buprenorphine in the Emergency Department .........................................................8 
      Rationale ......................................................................................................................11 
      Specific Aims ...............................................................................................................13  
Methods..............................................................................................................................14 
       Context ........................................................................................................................14  
       Intervention(s) .............................................................................................................16  
       Measures .....................................................................................................................18  
       Analysis.......................................................................................................................19  
  Ethical Considerations ................................................................................................20 
Results ................................................................................................................................20 
 Process Development ...................................................................................................20 
 Trainings ......................................................................................................................22 
 Tracking .......................................................................................................................24 
 Continuous improvement adjustments during implementation ...................................26 
Discussion ..........................................................................................................................27 









 Appendix A- Roger’s Diffusion of Innovation Model ................................................40 
 Appendix B- Institute for Healthcare Model for Improvement ...................................41 
 Appendix C- Buprenorphine Readiness Assessment Tool ..........................................42 
 Appendix D- WDH Opioid Withdrawal Guideline .....................................................46 
 Appendix E- WDH Buprenorphine Home Induction Guideline..................................52 
 Appendix F- Trainings Resources ...............................................................................59 
 Appendix G- ED-Initiated Buprenorphine Pilot- Case Reporting Form .....................61 
  Appendix H- WDH letter approving project as quality improvement .........................62 
















Background:  Emergency department (ED) visits for opioid related visits have increased 
dramatically during the opioid epidemic.  Buprenorphine is an evidence-based therapy for 
treating opioid use disorder (OUD) and withdrawal. Unfortunately, lack of access to 
pharmacotherapy for OUD, including buprenorphine, remains a challenge. Research supports 
ED-initiated buprenorphine as a practical, cost-effective strategy which engages patients in 
treatment better than non-pharmacologic alternatives. 
 
Purpose: The aims of this improvement project were to 1) develop a pilot process in an ED for 
providing buprenorphine to patients in opioid withdrawal or for OUD; 2) recruit and train a 
cohort of ED staff on the process; and 3) track the process as it was offered to patients. 
 
Methods/Interventions: Based on protocols from national and regional examples, a process for 
ED-initiation of buprenorphine was developed. Using a Diffusion of Innovation model, the 
project trained an influential cohort of staff.  Buprenorphine waiver training was facilitated for 
ED physicians.  In-person and virtual trainings on the process were conducted by the project 
leader.  Written case reports for patient encounters were completed by providers/staff.  
 
Results:  Guidelines were vetted and approved by hospital committees. 6 out of 10 full-time 
ED physicians (60%) obtained buprenorphine waivers. Pilot program trainings were provided 
to 34 staff directly and a recorded training was distributed. Within the first month of 
implementation, 16 unique case reports of encounters were collected. Case reports showed 
high rates of adherence to the following steps of the process:  COWS scores performed 
(87.5%), buprenorphine administered for COWS score ≧8 (100%) discharged with 
prescription after ED dosing (77.8%), home induction prescriptions for COWS<8 (100%), 
cases discharged with prescription (87.5%), and referral to care coordination services 
(81.25%).  Lower rates of adherence to process steps of involvement of recovery coaches 
(56.25%) and provision of overdose education/naloxone (33.3%) were noted.  Process barriers 
included difficulties with entries in electronic medical record (EMR), a patient who did not get 
relief, and a patient who declined buprenorphine. Suggestions for improvement included easier 
order entry, clearer documentation of COWS score and challenges in locating forms.   
 
Conclusion: This project resulted in a new ED process affording access to buprenorphine 
where it was previously unavailable.  A majority of ED physicians (60%) became waivered to 
prescribe buprenorphine. This percentage is well above a targeted 13.5% to reach a critical 
mass hypothesized to sustain a diffusion of this innovation. The odds of improved outcomes 
resulting from buprenorphine exposure including sustained recovery and reduced overall 
morbidity and mortality for patients exposed in this project are improved. Despite limitations 
in data accuracy, lessons learned about the process including barriers and opportunities for 
improvement may be valuable to other organizations as they develop their own systems. 
Further analysis of the project including future statistical process control measures and 
collection of more data using the electronic record will be valuable. 
 
Keywords: opioid use disorder, opioid withdrawal, buprenorphine, emergency 
department, quality improvement 
ED-INITIATED BUPRENORPHINE  5  
 
 
A Pilot of Emergency Department-Initiated Buprenorphine for  
Opioid Withdrawal and Opioid Use Disorder 
 
Problem Description 
The United States is facing an ongoing opioid epidemic responsible for shocking societal 
complications, including historically high numbers of overdose deaths.  In 2017, the CDC 
reported nearly 72,000 overdose deaths, of which over two-thirds were linked to opioids 
(Ahmad, Rossen, Spencer, Warner & Sutton, 2018).  To make matters worse, overdose deaths 
represent only the tip of the proverbial iceberg of numerous other opioid-related health, social 
and economic costs. These include high healthcare burden related to infectious diseases and non-
fatal healthcare for opioid related problems, lost work productivity, criminal justice costs, and 
generational trauma related to loss of loved ones to name only a few. In a recent report, the 
White House Council of Economic Advisers (November 2017) estimated that the total costs of 
the epidemic for 2015, were $504 billion.   
In the face of this public health crisis, consideration of evidence-based treatment for 
people who develop opioid use disorder is paramount.  Research supports the use of 
pharmacotherapy including opioid agonist therapy (methadone and buprenorphine) as effective 
lifesaving treatment for opioid use disorder (OUD).  Buprenorphine in particular has been shown 
to be an effective tool for both maintenance treatment (Mattick, Breen, Kimber, & Davoli, 2014) 
and management of opioid withdrawal symptoms (Gowing, Ali, White, & Mbewe, 2017).  Given 
the increased prevalence and urgency of the epidemic, wider access to pharmacotherapy is called 
for and non-traditional venues for initiating and accessing treatment are necessary.  Emergency 
departments (ED) in hospitals frequently serve as the healthcare venue for opioid related visits 
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and thus represent a setting where expanded access to pharmacotherapy including buprenorphine 
should be considered.   High quality research supports ED-initiated buprenorphine as a practical, 
cost-effective strategy which engages patients in short-term treatment better than non-
pharmacotherapy alternatives (Busch et al., 2017, D’Onofrio et al., 2015, D’Onofrio et al., 2017).   
Available Knowledge 
The opioid epidemic and emergency departments.  The tragic number of drug-related 
overdose deaths in the U.S. are dismaying.  In 2017, the total number of overdose deaths totaled 
more than the number of all soldiers killed in the entire Vietnam war, more than the number of 
peak annual HIV/AIDS or gun deaths in the 1990’s, and more than annual peak motor vehicle 
accident deaths in the 1970’s (Lopez, 2017).  In 2016, New Hampshire ranked 2nd in the nation 
for per capita rate of overall overdose deaths and 1st for fentanyl related overdose deaths (Centers 
for Disease Control and Prevention (CDC), 2017).  
Over a one-year period from 2015-2016, the CDC found that the number of ED visits for 
opioid overdose, which represents only a fraction of total opioid-related visits, increased 
nationwide by nearly 30% (Vivolo-Kantor et al., 2018).  In New Hampshire, opioid-related visits 
to EDs increased 9.8% from 2016-2017 to over 50 visits per month per 10,000 population 
statewide (NH Drug Monitoring Initiative [NH DMI], 2018).  Also, in 2016-2017, in Strafford 
County, where the project site (Wentworth Douglass Hospital: Mass General Subsidiary [WDH]) 
is located, the number of opioid-related ED visits per capita of 71.22 visits per 10,000 population 
was the highest of all counties in NH (NH DMI, 2018). The combined high prevalence of opioid 
related health problems in NH and the frequency of ED visits related to opioids, suggest that the 
ED is an ideal setting for improved interventions aimed at enhancing outcomes for patients.   
Pharmacotherapy for OUD. It is widely accepted that pharmacotherapy (often referred 
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to as “medication assisted treatment”) for opioid use disorder is an evidence-based and lifesaving 
treatment.  Both methadone and buprenorphine are listed on the World Health Organization’s 
(WHO) (2005) list of essential medication, citing their success in reducing heroin use as well as 
being associated with numerous other public health and societal benefits such as reduced rates of 
HIV, hepatitis, and criminal activity. Of the three current approved medications for treatment of 
opioid use disorder in the US, buprenorphine, a partial opioid agonist, has some practical 
advantages over methadone and naltrexone.  Pharmacologically, buprenorphine, unlike 
methadone, poses less risk of overdose due to its ceiling effect where larger doses do not 
suppress respiratory drive.  Moreover, whereas current federal law requires daily observed 
dosing of methadone in licensed treatment facilities, buprenorphine may be prescribed by any 
provider who has received a Drug Enforcement Agency waiver after completing a training 
(Substance Abuse and Mental Health Services Administration (SAMHSA), 2018).  Unlike 
naltrexone, a full opioid antagonist, buprenorphine can be used for symptomatic relief of opioid 
withdrawal symptoms.  In a Cochrane Review metanalysis, Gowing, Ali, White, & Mbewe 
(2017) found buprenorphine to be more effective than non-opioid clonidine or lofexidine for 
management of opioid withdrawal.  Buprenorphine resulted in less severity of withdrawal 
symptoms, shorter duration of withdrawal treatment and increased likelihood of completing 
treatment (Gowing et al., 2017).  This review also found buprenorphine to be as effective as 
methadone for managing withdrawal (Gowing et al., 2017). There is also evidence that repeated 
exposure to buprenorphine, even if initial treatment is not successful in long-term treatment 
retention, may result in better treatment retention in subsequent buprenorphine treatment 
(Cunningham, Roose, Starrels, Giovanniello, & Sohler, 2013). This finding is key to address the 
myth that ED-initiated buprenorphine should only be prescribed when a comprehensive follow 
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up plan is in place before discharge.  
A recent systematic review and meta-analysis showed that buprenorphine for OUD is 
effective for reducing illicit drug use, improving physical and mental health morbidity and 
reducing overall mortality (Sordo et al., 2017).  Buprenorphine has been shown to be an effective 
and relatively safe medication for both opioid withdrawal as well as maintenance treatment for 
OUD (Gowing et al, 2017; Mattick et al., 2014).  In a 2016 study of 150,000 National Health 
Service patients treated for OUD and followed for over 400,000 patient years, treatment with 
buprenorphine reduced the risk for opioid overdose death by 50% compared to patients with no 
treatment or psychosocial treatment alone (Pierce et al., 2016). 
The efficacy and relative safety profile of buprenorphine, combined with its availability 
outside of specialty addiction treatment clinics, makes it the principal tool to combat the 
devastating effects of the opioid epidemic. Although relatively new within the US, 
buprenorphine’s benefits have been demonstrated in other countries. To address a worsening 
opioid epidemic in 1995, France lifted prescribing restrictions for buprenorphine which led to 
dramatic increases in patients treated with buprenorphine and a 79% reduction of overdose 
deaths between 1995-2004 (Auriacombe, Fatséas, Dubernet, Daulouède, & Tignol, 2004).  
Buprenorphine in the emergency department.  Because the opioid crisis has resulted 
in numerous ED opioid-related visits, utilizing buprenorphine for opioid withdrawal 
management and as initiation of OUD treatment in the ED is a clear fit. In a currently 
unpublished systematic review, Hale and Lucey (2018) identified three studies that assessed ED-
initiated buprenorphine including a randomized control trial (RCT) (D’Onofrio et al., 2015), a 
cohort follow-up study (D’Onofrio et al., 2017) and a cost-effectiveness analysis of the RCT 
(Busch et al., 2017).  Using a validated Downs and Black checklist, the authors independently 
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and then jointly assessed the quality of the included studies and determined quality to be high 
despite some limitations and a risk of attrition bias in two of the studies (Hale & Lucey, 2018).  
D’Onofrio et al. (2015; 2017) demonstrated that ED initiation of buprenorphine resulted in 
improved retention in treatment compared to both a psychosocial brief intervention and referral 
to treatment resources without motivational counseling. ED initiation of buprenorphine was 
found to be cost-effective and superior to brief intervention and referral at all willingness-to-pay 
values above zero dollars (Busch et al., 2017).   
 Across these 3 studies, ED-initiated buprenorphine resulted in higher treatment retention 
at 30 days and 2 months compared to both brief intervention and referral to treatment without 
psychosocial intervention.  Although the intended N of 360 for the RCT (D’Onofrio et al., 2015) 
was not achieved resulting in a slightly underpowered study, the significantly improved retention 
rates for the buprenorphine group at 30 days and 2 months is convincing evidence that ED 
initiation of buprenorphine results in better outcomes than non-pharmacologic ED care. 
Although improvements were also seen in both non-medication arms of the study, it is important 
to consider that both control arms received more attention to OUD than current standard in US 
ED’s (D’Onofrio et al., 2015). 
ED-initiation of buprenorphine was found to be significantly more cost-effective, than 
both non-pharmacological ED interventions (Busch, et al., 2017). Compared to non-
pharmacologic interventions, ED-initiated buprenorphine had significantly lower patient time 
costs ($97 versus $283–322; P < 0.001) (Busch, et al., 2017).  Additionally, the initial cost of 
training ED providers to receive waivers to prescribe is also low.  The cost effectiveness analysis 
did not include factors such as labor market improvements, reduced disease transmission from 
patients engaged in treatment, and family benefits of patients engaged in treatment. Therefore, 
ED-INITIATED BUPRENORPHINE  10  
 
the overall cost benefits of ED-initiated buprenorphine are likely underestimated (Busch, et al., 
2017).    
 Although studies specific to ED initiated buprenorphine are few, the significant positive 
results of higher treatment retention and cost-effectiveness of ED-initiated buprenorphine 
warrant larger scale implementation and further research.  There is strong evidence showing 
buprenorphine as a safe, lifesaving, and effective treatment for both opioid withdrawal and OUD.  
This evidence asserts that more hospitals and ED providers should innovate and begin to use this 
proven medication in ED venues where patients with OUD often present for care.  In fact, in a 
consensus report released during this project’s timeline, the National Academies of Sciences, 
Engineering, and Medicine (2019) concluded that “withholding or failing to have available all 
classes of FDA-approved medication for the treatment of opioid use disorder in any care or 
criminal justice setting is denying appropriate medical treatment (p. 88).” In other words, failure 
to provide pharmacotherapy for OUD is unethical.   
Efforts to expand ED-initiated buprenorphine are ongoing in several areas across the U.S. 
in response to the opioid crisis and the evidence in support of ED-initiated buprenorphine.  In 
California, ED-Bridge is a program through the SAMHSA State Targeted Response to the 
Opioid Crisis Grant to the California Department of Health Care Services (ED-Bridge, 2018).  
This program aims to increase the number of California ED’s that offer 24/7 access to 
buprenorphine and offers several resources for starting and sustaining a program to initiate 
buprenorphine in the ED.   
While California’s efforts have thus far consisted of pilot programs in select hospitals, a 
2018 Massachusetts law mandated that all emergency departments have the capacity to initiate 
opioid agonist therapy (buprenorphine or methadone) to patients after an opioid-related overdose 
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(Bebinger, 2019).  In response to the law, the Massachusetts Health and Hospital Association 
(MHA) (2019) published “Guidelines for Medication for Addiction Treatment for Opioid Use 
Disorder within the Emergency Department.”  
On a national level, in September 2018, the National Institute on Drug Abuse (NIDA), in 
collaboration with researchers at Yale University, launched a web-based resource to help guide 
ED providers in best practices for use of buprenorphine in the ED setting (NIDA, 2018).  
Resources include tools for identifying OUD, training resources for interacting with and 
motivating patients towards treatment and a simple algorithm for buprenorphine initiation for 
eligible patients in the ED.   
Unfortunately, although the prevalence of substance use disorders including opioid use 
disorder is high, lack of access to proper treatment remains a national challenge.  According to 
the 2018 report, Facing Addiction in America: The Surgeon General’s Spotlight on Opioids, only 
about 1 in 4 people with opioid use disorder received specialty treatment within the last year (US 
Department of Health and Human Services, 2018).  Development and expansion of ED-initiated 
buprenorphine programs is an important component of expanded access aimed at reducing this 
treatment gap.   
 
Rationale 
 The rate of OUD and complications such as infectious disease and fatal opioid overdoses 
both in the US and in New Hampshire, where this project was conducted, is staggering.  There is 
a need for low-barrier access to readily available treatment for patients with OUD, of which 
pharmacotherapy is a cornerstone. Buprenorphine is a practical, lifesaving outpatient treatment 
that may be prescribed by trained providers across multiple settings including the ED. Expansion 
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of access to buprenorphine in ED settings is a critical component of a comprehensive public health 
approach to mitigating the enormous costs of the opioid epidemic.  Expansion of pharmacotherapy 
requires change within organizations to train prescribers, nurses, and staff and to overcome 
historical stigma and regulatory restrictions that have preferred less effective abstinence-only and 
psychosocial treatment modalities over pharmacotherapy.   
 The theoretical framework guiding this project was the Rogers Diffusion of Innovation 
Theory (Rogers, 2003).  Because ED-initiated buprenorphine was a new process for the WDH 
ED, it represented an innovative strategy that will undergo a process of diffusion before being 
widely used and accepted.  Diffusion is defined as a social process that occurs as people learn 
about a new evidence-based approach for improving healthcare (Dearing and Cox, 2018). 
Diffusion occurs over time and, as illustrated in Appendix A, typically follows an S-Shaped 
curve with an initial slow rate of adoption of the innovation and progressing to more rapid 
acceleration which eventually slows as less non-adopters remain and the innovation has become 
the standard (Dearing and Cox, 2018).  With clinical practice changes that rely on voluntary 
adoption of certain practices, the rate of adoption can be accelerated by influential members of 
the social system of interest (early adopters) who then communicate the benefits of the 
innovation to others who follow their lead (Dearing and Cox, 2018).  It was the intent of this 
project to train and utilize a critical mass (greater than 13.5%) of ED provider “early adopters” to 
begin offering ED-initiated buprenorphine in the hopes that a “tipping point” would be reached 
and subsequent ED access to evidence based pharmacotherapy would then become standard over 
time as the innovation diffuses over the entire social system of ED providers.   
The success of an innovation’s diffusion generally relies on 3 sets of variables: the 
inherent pros and cons of the innovation, the characteristics of the adopters, and the larger social 
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and political context in which the innovation arises (Dearing & Cox, 2018).  For this project, the 
convincing evidence in support of ED-initiated buprenorphine pointed to it as a likely successful 
innovation.  The characteristics of the ED early adopter providers, which included the medical 
director, the nurse manager and several respected ED physicians and nurses, suggested that these 
members of the social system would be successful in influencing their peers towards adoption.  
Lastly, because of the overwhelming urgency of the opioid epidemic and the sociopolitical 
attention being paid to improving the health of the community affected by opioids, this 
innovation was highly timely and pertinent.   
As a quality improvement effort, this project was also guided by the Institute for 
Healthcare Improvement Model for Improvement (Appendix B).  IHI guiding principles of 
forming a team, setting aims, establishing measures, and selecting/ testing/ implementing/ 
spreading changes were used.  Because this project aimed to establish a new process for the 
WDH ED, traditional statistical process control techniques to measure the process over an 
extended period were not indicated.  The project leader communicated regularly with WDH and 
ED leadership, providers, nurses and staff. Based on the analysis of case report data, adjustments 
and improvements were made, through multiple PDSA (Plan, Do, Study, Act) cycles as the 
process of ED-initiated buprenorphine was developed and implemented.  
Specific Aims 
 The goals of this project were to develop and pilot a process for ED-initiated 
buprenorphine, to train early adopter providers and staff to administer and prescribe 
buprenorphine in the ED, and to track the process as buprenorphine was offered.  The project’s 
specific aims were as follows:  
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1. By December 30, 2018, in collaboration with WDH behavioral health and ED leadership, 
ED staff, and select community buprenorphine providers, develop a pilot process for 
initiating buprenorphine treatment for ED patients presenting with opioid withdrawal or 
requesting outpatient OUD treatment. 
2. By January 30, 2019, at least 3 full-time ED physician providers would be trained and 
waivered to prescribe buprenorphine.  At least 6 ED nursing staff would also be trained 
on buprenorphine and the WDH process for ED initiation.   
3. By March 8, 2019, tracking of the ED buprenorphine initiation process would be initiated 
using case report data where buprenorphine was offered or provided to patients. 
Descriptive statistics on process steps as well as reported barriers and opportunities for 




Wentworth Douglass Hospital-Massachusetts General Hospital Subsidiary (WDH) is a 
178-bed community Magnet® Recognized hospital located in Dover, NH. In 2017, WDH joined 
the Massachusetts General Hospital family and Partners HealthCare system. WDH serves the NH 
and southern Maine Seacoast and in addition to the hospital operates several walk-in clinics, 
primary care and specialty offices, a dental clinic, a fitness center and a philanthropic foundation 
(WDH, n.d.).  The community of Dover and the state of NH have been dramatically affected by 
the opioid epidemic which has had several adverse effects including a strain on emergency services 
with over 6500 emergency visits in NH and nearly 900 visits in Strafford County (where WDH is 
one of 2 hospitals) related to opioids in 2017 alone. (NH DMI, 2018)    
ED-INITIATED BUPRENORPHINE  15  
 
 This project not only met the need for an evidence-based response to the New Hampshire 
and Strafford County opioid crisis but also fit in to specific strategic planning measures 
documented by WDH: The hospital system’s long-range plan includes “strengthening, 
enhancing, and growing programs and services to meet the health care needs of the communities 
we serve” (WDH, 2018, p.3).  More specific to OUD and the importance of pharmacotherapy, 
the mission of WDH strives to partner with patients to “attain their highest level of health” by 
promoting “patient-centered and evidence-based” approaches (WDH, 2018, p.4).  Additionally, 
within its identified strategic priorities, WDH looks to “optimize, coordination and improve 
transitions of care across the continuum” and “strengthen access to and coordination of 
behavioral health services” (WDH, 2018, p.7).  Efforts to expand access to pharmacotherapy for 
OUD fit clearly in these goals.  Another strategic priority for WDH is to “boldly innovate health 
care delivery” with a focus on exploring, designing and testing new models of consumer-centric 
care (WDH, 2018, p.7).  This project represents a key innovation in consumer-centric care.   
In addition to its long-range strategic plan, in its 2016 Community Health Needs 
Assessment and Implementation Plan, WDH identified substance use disorder treatment access 
and resources as one of 10 of the community’s priority health needs and frequently references 
goals and initiatives in line with this project.  WDH (2016) commits to continuing the provision 
and expansion of behavioral health services and identifies a need to develop and implement 
educational trainings around behavioral health needs and resources for its providers and staff.  
Specifically targeting substance misuse and access to treatment, WDH reported a need for 
program initiatives exploring community partnerships for substance use treatment and increased 
access to specialists trained in addiction treatment.  Additionally, WDH (2016) committed to 
exploring the expansion of outpatient treatment options for substance use disorder and 
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implementing additional trainings about substance misuse for staff.   This ED-initiated 
buprenorphine project compliments these goals by training ED staff and by establishing 
connections with community buprenorphine providers.   
Primary stakeholders involved in this improvement project included ED providers/ nurses/ 
staff, behavioral health leadership and staff, ED leadership (nursing and medicine), the Strafford 
County Integrated Delivery Network (IDN), outpatient community buprenorphine providers, 
social work services, and recovery coach services provided by SOS Recovery, the local recovery 
community organization.  
Intervention(s) 
To achieve the above stated aims, the following interventions were carried out:   
Pre-implementation (August-November). Initial concepts of the project began after the 
project leader, an ED nurse practitioner with expertise in addiction, was approached by the WDH 
behavioral health director and ED leadership.  After reports of patient dissatisfaction with opioid 
withdrawal management were expressed by staff of the recovery coaching program within the 
hospital, a meeting to discuss options for improving care for opioid withdrawal was convened by 
the director of behavioral health.  Attendees of this initial meeting included the project leader, 
ED leadership (nurse manager and medical director), the behavioral health medical director, 
hospitalist medical director, and outpatient practices medical director.  From this discussion, it 
was decided that piloting a program for ED-initiated buprenorphine would be an important step 
towards improved care for patients with opioid withdrawal.  
An organizational readiness assessment tool produced by the Network for the 
Improvement of Addiction Treatment (NIATx) at the University of Wisconsin–Madison 
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(Appendix C) completed by the project leader confirmed that the WDH context represented an 
excellent site for buprenorphine implementation.    
Implementation (December-April).  
Process development. The project leader arranged multiple meetings/communications 
with the WDH behavioral health director, ED leadership, early adopters, community providers, 
and the Strafford county IDN to develop the WDH ED-initiated buprenorphine process.  
Guidelines were produced describing step-by-step plan for ED-initiation including inclusion/ 
exclusion criteria, an initiation protocol consistent with expert recommendations and NIDA 
(references), and instructions for outpatient referral and follow-up.  The project leader obtained 
examples of Mass General Hospital’s ED-initiation protocols to serve as reference for adaptation 
to a WDH-specific process.  Two guidelines were extensively reviewed by stakeholders, revised 
and ultimately approved by hospital Standardization and Pharmacy and Therapeutics Committee 
(Appendices D and E).     
Trainings.  In collaboration with partners and stakeholders, the project leader facilitated 
buprenorphine waiver trainings for early adopter prescribers.  After encountering multiple 
challenges in coordinating schedules for an in-person federal DEA waiver training, asynchronous 
online trainings for individual providers were determined to be the most effective way of 
obtaining waivers.  The project leader distributed information to all ED providers directing them 
to online trainings or regionally available in-person trainings.  Many ED providers opted for the 
nationally-offered approved trainings at https://pcssnow.org/medication-assisted-treatment/.  
Once the process for ED-initiation was finalized and approved, the project leader 
developed and delivered in-person and virtual trainings on the process to ED and allied staff. A 
binder including copies of the approved guidelines, and supporting resources such as criteria for 
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diagnosing OUD, patient handouts, and a nursing guide for buprenorphine was placed in a 
central location in the ED.   A list of all training resources with links to specific documents is 
included in Appendix F. 
Case reporting. After the WDH process was approved and trainings were completed, 
data about the process was collected via written case report forms (Appendix G) filled out by 
staff after patient encounters involving buprenorphine initiation. Case report forms were 
deposited into a locked collection box and collected for analysis by the project leader/author 
only.  Although the ability to access medical records for auditing of encounters was desired, it 
was not permitted during the quality improvement project approval process.    
Budget. There were minimal economic costs to carry out this project.  Online waiver 
trainings were federally-sponsored and free of charge.  Process trainings were available as an 
asynchronous recorded training or delivered as drop-in trainings during ED shifts thus relieving 
the need to pay staff for extra training time.   
Measures 
 To measure the outcomes of this project the following instruments were used:  
Process development. An organizational readiness assessment tool created by the 
Network for the Improvement of Addiction Treatment (NIATx) at the University of Wisconsin–
Madison (Appendix C) indicated that WDH was an organization well-suited to implementation 
of a buprenorphine program with a total relative score of 18 or “Excellent”.  Approval of the 
written process guidelines through the hospital Standardization and Pharmacy and Therapeutics 
Committees served as the final outcome measure of process development.   
Training.  Descriptive data on numbers of providers obtaining buprenorphine waivers 
and numbers/ types of staff receiving in-person process trainings were collected.   
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Case Reporting. Data on patient encounters was measured using case report forms 
(Appendix G).  Data collected included: initials of staff involved to avoid duplication of data if 
multiple staff compete forms on same encounter , date/time of patient encounter, questions about 
the process algorithm points (whether patient was in withdrawal, if a Clinical Opioid Withdrawal 
Scale (COWS) was used, if buprenorphine was dosed in ED, if a prescription was given at 
discharge, and if overdose education was provided), where the patient was referred, and if a 
follow-up appointment was made.  Additionally, respondents were asked to comment on barriers 
encountered and to suggest potential improvements to the process.  
Analysis 
A description of process development steps and descriptive statistics on the training 
phase of the project were summarized for review.  Case report data were compiled at the end of 
the pilot project timeline and summaries of descriptive statistics (i.e. number of encounters 
reported, number of times buprenorphine was initiated, locations of community referrals) were 
reviewed.  Evaluation of the fidelity to the treatment algorithm steps was performed with 
attention to calculation of COWS scores and appropriate induction dosing (ED or home 
induction) (Table 2).  Data on barriers and suggestions for improvement was tallied and reported.  
Because the process is new, traditional statistical process control reporting (i.e. run charts, p-
charts) was not possible during the project timeline as numbers of encounters were not sufficient 
and access to all ED records for analyzing total numbers of patients seen for opioid-related visits 
was not permitted. 
In addition to analysis of written case reports, the project leader met with multiple 
stakeholders (ED providers, staff, Doorway staff, recovery coaches, and pharmacists) during 
ED-INITIATED BUPRENORPHINE  20  
 
project implementation and received feedback which guided adjustments and suggestions for 
potential future process improvements.   
Ethical Considerations 
 This project was approved by WDH as a quality improvement project by the WDH Nurse 
Scientist and Director of Nursing Education, Research & Innovation (Appendix H).  The 
University of New Hampshire (UNH) School of Nursing’s Quality Review Committee reviewed 
and recognized this project as a quality improvement project not requiring IRB approval 
(Appendix I).  As a quality improvement project, no personally identifying patient information 
was collected. Any review of patient/staff information was conducted by personnel with 
permission to access data for provision of clinical care.  All data presented as part of this project 
is aggregated data.  Staff initials collected on case report forms were only used by the project 
leader to determine if multiple encounter forms were completed on the same patient encounter 
and are de-identified in reporting of results. The risks and benefits to patients participating in this 





Guidelines for opioid withdrawal and OUD treatment with buprenorphine (Appendices D 
and E) were approved in March 2019.  Although the original timeline of this project estimated 
approval by December 2018, several delays in achieving stakeholder consensus extended the 
timeline.  Formal approval by the WDH Standardization Committee (end of February 2019) and 
then the WDH Pharmacy and Therapeutics Committee (mid-March 2019) was required, which 
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was not originally anticipated.  The first patient encounter resulting in ED buprenorphine 
initiation occurred one day after guidelines were approved in March 2019.   
Process development consisted of multiple meetings between stakeholders, consultants 
and the project leader, which are further described in methods.  Expert colleagues from Mass 
General Hospital, the first Massachusetts hospital to offer ED initiated buprenorphine (Bebinger, 
2018), shared protocols with the project leader which served as a foundation for the WDH 
guidelines.  To enhance outpatient support and follow-up, recovery coaches were utilized during 
encounters for ED-initiated buprenorphine.  Guidelines specify definitions of patients 
appropriate for buprenorphine initiation and include detailed assessment steps such as diagnostic 
criteria for OUD and a validated opioid withdrawal assessment tool (Clinical Opioid Withdrawal 
Scale [COWS]).  Medication orders for buprenorphine and discharge process steps are specified.  
The guidelines utilized the NIDA recommended algorithm for ED-Initiated Buprenorphine 
(Figure 1).  Two separate guidelines, representing the 2 main branches of the NIDA algorithm, 
were approved. One for use with patients in acute withdrawal (COWS score >8) who would 
require buprenorphine dosing in the ED and another for patients who would qualify for home 
induction by outpatient prescription (COWS scores <8).    
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Figure 1- From: https://www.drugabuse.gov/nidamed-medical-health-professionals/discipline-specific-resources/initiating-
buprenorphine-treatment-in-emergency-department/buprenorphine-treatment-algorithm  
 
Coinciding with this project, in January 2019, WDH became one of 9 state “hubs” and 
opened The Doorway, a service to assist anyone seeking treatment for substance use (Early, 
2019).  Whereas the original intent of the project was to have several options of community 
buprenorphine providers available to refer patients to at discharge, the Doorway made it possible 
to refer patients to one location where care coordination of follow-up (i.e. insurance coverage, 
transportation needs, preferences of location for follow-up) was addressed by Doorway staff.   
Trainings 
As of February 2019, a total of 6 full-time ED physician providers had been trained and 
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waivered to prescribe buprenorphine.  This represents 60% of the full-time ED physician staff at 
WDH, a percentage above the originally targeted 13.5% based on the Diffusion of Innovation 
theory (Dearing and Cox, 2018).  As indicated in Table 1, multiple ED staff including 14 nurses 
and 17 interdisciplinary staff trained onsite. A recorded training was distributed to all other ED, 
behavioral health and social work staff. 
Table 1 
ED Buprenorphine Trainings 
Buprenorphine Waiver Trainings 
Type of Training Number/Type of Staff 
• In-person Buprenorphine Waiver 
Training (offered by regional trainers) 
1 Physician 
 
• Online Buprenorphine Waiver training 5 Physicians 
WDH Process Trainings 
• Drop-in onsite trainings by Project 
Leader 
6 MAT Waivered Physicians 
14 Nurses 
4 Physician Assistants 
4 Social Workers 
3 Recovery Coaches 
2 Psychiatric Nurse Practitioners 
2 Pharmacists 
1 Behavioral Health Clinician 
1 Paramedic 
• Recorded Process Training Distributed by email to all ED/ Behavioral 
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Health/ Social Work staff 
Tracking 
Beginning March 2019, tracking of ED-initiated buprenorphine was initiated to track 
when buprenorphine was offered or provided to patients. In the first month of the process, 16 
unique case reports were collected. Additionally, one case report was filed where a patient was 
offered buprenorphine but declined.  Table 2 illustrates various steps of the algorithmic process 
and the rates of compliance with the process.  COWS scores were performed on 14 patients 
(87.5%).  Nine case report forms documented a COWS score of ≧8, five documented a COWS 
<8, and two did not have a COWS score reported. As EMR access was not allowed by the 
project site, it is unknown whether a COWS score was documented in the patient’s chart but 
omitted from the case report form. Buprenorphine was administered in the ED for all nine 
patients with a recorded COWS score ≧8 (100%). One patient received ED dosing, but a 
waivered provider was unavailable to write a discharge prescription. One patient was 
administered buprenorphine in the ED but eloped prior to receiving a prescription.  Home 
induction prescriptions were provided for seven patients total, including the five with a 
documented COWS <8 (100%) and the two patients who did not have a COWS score reported.  
Discharge prescriptions for buprenorphine were provided to 14 of the 16 patients with case 
reported filed (87.5%). Of the nine encounters that documented whether overdose 
education/naloxone was provided, three of the nine (33.3%) indicated that it was.  The Doorway 
was the only referral source with 13 patients (81.25%) referred to its care coordination services.  
Recovery coaches were involved in nine out of 16 encounters (56.25%).  
Table 2 
ED Buprenorphine Initiation Process Compliance Analysis 
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Process Step n  Total applicable cases  Percent 
Compliant 
COWS Performed and 
Documented on Case 
Report 
14 16 87.5 
Buprenorphine Dosed 
in ED (COWS >8) 
 
9 9 100 
Discharged with 
Prescription (RX) 
After ED Induction 
7 9 77.8 
Home Induction RX 
Provided for COWS 
<8 
7 7 100 
Cases Where RX 
Given at Discharge 
(Waivered Provider) 




3 9 33.3 
Referred to Doorway 
 
 




9 16 56.25 
 
Table 3 includes reported barriers encountered by staff as well as suggestions for process 
improvements.  Barriers to the process identified by staff included difficulties with inputting 
orders and writing prescriptions within the existing electronic medical record (EMR), a patient 
who did not get relief, and a patient who was not interested in medication for treatment. 
Suggestions for improvement included easier inputting of orders and prescriptions in the EMR, 
clearer documentation of COWS score in the EMR, locating forms in a central location, and 
ensuring follow-up arrangements.   
Table 3 
Barriers Encountered and Potential Improvements 





• “Patient stated did not get relief from dosing in ED” 
• “Patient actively using (while in ED no less) and not ready 
to start med or accept change in lifestyle. Left AMA 
(against medical advice).” 
• “Putting in RX in ED electronic record was laborious” 
• “Computerized Physician Order Entry (CPOE) one-time 
orders are not well-built” (2 instances) 






• “It would be great if it was easier for providers to order” 
• “Easier entry of RX into ED electronic record” 
• “Clear documentation of COWS score in EMR. As a 
pharmacist, I would like to know the score and symptoms in 
case any additional treatment/symptom care can be 
recommended” 
• “All forms in one location” 
• “Assuring follow-up appointment as soon as possible” 
• “Patient also received Ativan in ED. Patient qualified for 
8mg dose. Will send email as to whether to add 8mg tabs, 
because we only have 2mg tabs in ED.”   
• “Not sure if possible but definite follow-up arrangement 
would be helpful” 
 
 
Continuous improvement adjustments during implementation   
During implementation, the project leader collected feedback from case report forms and 
post-encounter conversations with staff to guide process improvement.  Examples of process 
issues that arose and adjustments are listed in Table 4.   
Table 4 
Continuous Improvements During Implementation 
Issue Adjustment/Improvement 
Original phone number listed for after-hours 
Doorway messages was changed. 
Guidelines updated with correct numbers. 
Binder updated. 
Order entry system did not allow for ordering 
buprenorphine films although films were 
stocked in Pyxis.  
IT was contacted, and films were added to the 
order options.   
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Inputting long instructions into home 
induction RX’s was laborious. 
Project leader printed “cheat sheets” at 
provider workstations and worked with IT to 
create “favorites” for easy input. 
Referrals coming from Doorway created 
concern about whether a waivered provider 
would always be available. 
Instructed Doorway to call ahead to ensure a 
waivered provider available. 
Patient who did not get an appointment before 
initial RX ran out, Doorway called to see if a 
refill could be issued. ED provider expressed 
discomfort in issuing refills and becoming a 
long-term bridge clinic.  ED provider 
expressed concern that refill requests would 
deter ED providers to prescribe initial 
prescription.   
Discussion with providers/ Doorway/ 
Behavioral Health director plan for bridge 
clinic, enhanced messaging to patients that 
ED bridge is intended to be short term and 
ideally one-time. Discussed ED provider 
flexibility for instances of legitimate repeat 
visits.  Follow-up meeting with ED providers/ 
Doorway planned. 
Hospital outpatient pharmacist expressed 
concerns about challenges filling RXs that 
indicate films or tabs as insurances often 
prefer one over the other.  Also concerned 
about length of home induction instructions. 
Edited guidelines/ “cheat sheets” to allow for 
interchange of tabs/ films and induction 





This project achieved all its specific aims of developing a process for ED buprenorphine 
initiation including training a cohort of providers/ staff and tracking the new process.  This project 
is an example of a successful diffusion of innovation and continuous improvement project that 
addressed a pressing clinical need for rapid access to evidence-based treatment for opioid 
withdrawal and OUD.  The project achieved an overarching goal of creating the availability of 
buprenorphine in the ED, where it had not been available to patients before. Given the current 
regional and national opioid epidemic and its associated tragic burdens, this project may serve as 
a model for other organizations looking to implement rapid access to buprenorphine for OUD.   
Particular strengths of this project include the work and dedication of the early adopter 
staff at WDH who showed enthusiasm and compassion towards a patient population that 
historically has not had easy access to care and evidence-based treatment.  In just over a month of 
ED-INITIATED BUPRENORPHINE  28  
 
data collection, at least 14 patients were started on buprenorphine. Because data collection in this 
project was restricted to voluntary written case reports, true numbers of patient initiations are likely 
higher. High rates of compliance with several steps of the process algorithm (Performance of 
COWS, Buprenorphine dosing in ED for COWS ≥ 8, Home Induction RX’s, RX’s at discharge, 
referrals to Doorway) demonstrate fidelity to the process as developed and implemented.  
However, other steps in the process with lower rates of compliance, namely overdose education, 
naloxone distribution, and recovery coach involvement, highlight the need for continued process 
improvement.  
Barriers identified by staff involved challenges with order entry and use of the EMR 
system.  Similarly, several suggestions for improvement involved efficiency or clarification of 
order entry and documentation within the EMR.  Other suggestions included stocking of different 
medication formulations in the hospital pharmacy and enhancement of follow-up appointments 
coordination. Additionally, the project leader was able to establish effective relationships with 
practice partners and seek continual feedback during implementation. The project leader was able 
to work with staff to successfully address each barrier identified.  
Interpretation  
This de novo process for initiating buprenorphine in the ED allowed providers and staff to 
offer a previously unavailable treatment that more effectively manages withdrawal, enhances 
engagement in treatment, and quickly connects patients to ongoing outpatient treatment in the 
community. After the Doorway had been able to send multiple patients to the ED for 
buprenorphine, the Doorway program manager provided feedback that “those are people we 
otherwise would have had essentially tell to go and use (illicit opioids)” to avoid severe withdrawal 
as they waited for access to community treatment services (P. Fifield, personal communication, 
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4/10/2019). The simple fact that there is now a safer alternative option for managing withdrawal 
and treating OUD available to patients in this community is a significant accomplishment. 
Training of a cohort of early adopter ED providers, who model the benefits and use of this 
new ED process to other providers, is expected to result in continued and expanded use of this 
innovative intervention.  It is hoped that with more universal use and experience with the process 
that more providers will become trained and waivered.  Subsequently, opportunities for ED patient 
engagement and treatment for OUD will be increased. Continual collaboration with recovery 
coaches and behavioral health care coordination services (the Doorway) to ensure prompt and 
sustained outpatient engagement will be critical to the success.   
While this project did not intend to measure or replicate longer term outcome results of 
other research, based on previous studies of ED-initiated buprenorphine, the intervention that is 
now available at WDH increases the odds for patients remaining in treatment (D’Onofrio et al., 
2015). This should in turn, decrease their overall risk of morbidity and mortality (Sordo et al., 
2017).  Further research to confirm this hypothesis is needed.  Another potential benefit of this 
project is that with repeated exposure to buprenorphine, even if patients do not engage in follow 
up, odds of retention in treatment are increased over time and exposures (Cunningham et al., 2013).  
This project represents a concrete action within the organization to improve the care of 
patients with opioid use disorder, which is consistent with WDH’s stated strategic plans for 
improving community health.  The advent of WDH opening the Doorway as a centralized referral 
site and the availability of recovery coaches in the ED were beneficial to the success of this project. 
As this intervention continues, it will be important for the WDH system to ensure prompt follow-
up for ongoing treatment after ED-initiation to minimize repeat ED visits for buprenorphine refills 
as some ED providers expressed an unwillingness to refill and if asked to do so, this might 
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jeopardize their willingness to prescribe at all.   
Limitations 
 This project does have several limitations.  Generalizability to other organizations may be 
limited as this project was conducted at one community hospital.  Access to addiction expert 
consultants (i.e. project leader, Mass General colleagues) may not be readily available to all 
other organizations.  Additionally, specialized services such as on-call recovery coaches and the 
Doorway referral site may not be available in other organizations.  Waiver training of providers 
was voluntary and while a majority of ED providers participated, the same result may not be 
expected in other organizations as the project leader had a longstanding relationship with 
providers.   
Unfortunately, several written case reports in this project were incomplete.  Missing data 
on case reports could have either a positive or negative effect on results. Because case reports 
were isolated from EMR documentation and there was not constant oversight to ensure 
completion, voluntary completion of reports in a very busy ED environment likely resulted in 
incomplete and missed reports.  To minimize the effect of missing data, the project leader gave 
several reminders to enhance reporting during multiple site visits as well as via email to 
providers.  Ideally, a strategy for maximizing reporting via consistent reminders either embedded 
within the EMR or access to a web-based survey may improve reporting.   
The inability to access data within the EMR also limited capacity for gathering more 
accurate and detailed data and prohibited the use of statistical process control measures.  Because 
this was a brand-new process with only a limited number of encounters recorded, data was 
insufficient to assess long-term trends.  Moreover, because EMR access was not granted, an 
accurate count of the total number of opportunities for buprenorphine initiation was not possible.  
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Without being able to assess the true denominator, it is not possible to assess the proportion of 
cases where the process was appropriately offered.  It would be ideal to audit the EMR for 
presenting complaints, discharge diagnoses, and buprenorphine orders (in ED and discharge 
RXs) to get more accurate data.  For future projects and/ or research, understanding of other 
variables surrounding visits for buprenorphine initiation (demographics, comorbid health 
conditions, frequency of ED utilization, number of repeat visits, etc.) would also be valuable.   
Conclusions 
 This project addressed a pressing need for the expansion of access to buprenorphine for 
patients with opioid withdrawal or seeking treatment for OUD.  The development of an ED 
buprenorphine initiation process created access to an evidence-based treatment for patients in the 
ED that was previously not available.  Training of a significant cohort of early adopters (60% of 
ED physicians, and multiple nursing and ancillary staff), larger than the targeted percentage, is 
expected to result in sustainability and continued diffusion of this innovative intervention.  
Tracking of the process revealed that multiple patients over a short period of time were exposed 
to buprenorphine, which according to previous research, is a safe, practical, effective treatment.  
It is hoped that outcomes for patients exposed will be similar to research outcomes showing 
improved rates of treatment as well as reduced morbidity and mortality.   
Given the nationwide epidemic of OUD with calls for the expansion of access to 
pharmacotherapy, including instances of legislated requirements like those in Massachusetts 
(MHA, 2019), it is probable that other organizations will pursue similar projects to offer ED-
initiated buprenorphine.  This project represents an example of one organization’s experiences 
with process development, training, and tracking.  While generalizability is limited in some 
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regards, the resources produced and experiences including lessons learned about barriers and 
suggestions for improvement may be valuable to other organizations.   
Next steps for further development of this project should strive to enhance efficiency and 
ensure sustainability.  In addition to targeting a goal for more ED providers to become waivered, 
it will be important to assess whether providers who are already waivered continue to offer 
buprenorphine.  An expected change to a new EMR in the next several months will require 
attention to process details like order entry and discharge information to ensure the process is 
better integrated within the new EMR.  Continued tracking of encounters through EMR audits 
would have improved accuracy and allow the ability to assess total numbers of eligible patients 
presenting to the ED to apply statistical process control measures for further improvement.   
Future related research might include evaluation of other outcomes such as patient 
satisfaction, patient demographics, short and long-term engagement in outpatient treatment, 
provider satisfaction, provider utilization of buprenorphine, rate of return ED visits, subsequent 
hospitalizations, and overdose rates.     
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Appendix A  
Roger’s Diffusion of Innovation Model 
 
(Dearing & Cox, 2018)  
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Appendix C 
Buprenorphine Readiness Assessment Tool 
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Guideline: ED buprenorphine for Opioid Withdrawal Protocol 
Applies to: Department of Emergency Medicine 
Effective Date: 3/20/19 
Reviewed and 
Approved by: 
Standardization Committee (Approved 2/26/19), P and 
T (Approved 3/20/19) 
Last Revision: 3/20/19 
 
Standards/Definitions:  
The following guideline has been developed to manage patients’ opioid withdrawal symptoms 
while being treated in the Emergency Department.  The guideline applies to patients who are 
actively going through opioid withdrawal. The active management of withdrawal symptoms is 
based on individual assessment and may vary based on specific clinical presentations.   
 
Recommendations in this guideline derived from: 
ASAM Clinical Practice Guideline: https://www.asam.org/docs/default-source/practice-
support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf 






Federal regulations permit the use of buprenorphine for a maximum of 72 hours for the purpose 
of relieving acute withdrawal symptoms while arranging for a patient’s referral to treatment. 
Patients who are eligible for the opioid withdrawal guideline must show active signs of 
withdrawal and be equal to or greater than 18 years old.  Appropriate conditions may include any 
of the following: 
1. Patients in the ED for an extensive period of time who meet Clinical Opioid Withdrawal 
Scale (COWS) criteria (Score > 8) for opioid withdrawal 
2. Patients in moderate-severe withdrawal (COWS >8) who are seeking assistance accessing 
treatment for their substance use and identified to have an opioid use disorder (OUD) in 
the course of their ER stay 
3. Pregnant women in withdrawal (COWS >8) –an OB consult is required for any pregnant 
patient.  Inpatient induction recommended for gestational age >20 weeks.  
Assessment 
a. Medical exam 
b. Identify patients with possible OUD (“How many times in the last year have you used 
heroin, fentanyl or prescription opioids for nonmedical reasons?” Any response more 
than “never” is a positive screen and warrants further assessment.) 
c. Assess eligibility for ED-initiated buprenorphine by meeting following criteria: 
o Recent regular opioid use (i.e. daily/almost daily use including within last 7 days) 
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o Meets DSM-5 criteria for moderate to severe OUD (4 or more criteria) 
o Opioids are often taken in larger amounts or over a longer period of time than intended. 
o There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
o A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, 
or recover from its effects. 
o Craving, or a strong desire to use opioids. 
o Recurrent opioid use resulting in failure to fulfill major role obligations at work, school 
or home. 
o Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
o Important social, occupational or recreational activities are given up or reduced because 
of opioid use. 
o Recurrent opioid use in situations in which it is physically hazardous  
o Continued use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by opioids. 
o *Tolerance, as defined by either of the following: (a) a need for markedly increased 
amounts of opioids to achieve intoxication or desired effect (b) markedly diminished 
effect with continued use of the same amount of an opioid 
o *Withdrawal, as manifested by either of the following: (a) the characteristic opioid 
withdrawal syndrome (b) the same (or a closely related) substance are taken to relieve 
or avoid withdrawal symptoms 
o Needs treatment (i.e. not already engaged in formal medication treatment program) 
 
d. Assess for signs and symptoms of withdrawal 














Utilize COWS scale (https://www.mdcalc.com/cows-score-opiate-withdrawal (also attached to 
end of this document) to determine if patient is in active withdrawal.  If COWS score is >8, 
consider ED induction.  If COWS<8, patient may be considered for Home Induction (See 
ED Buprenorphine/naloxone Home Induction Guideline).   
e. Consider: Urine tox screen, pregnancy test. Lab testing not required but urine tox can 
confirm opioid use and exclude recent methadone if concerned.  Consider LFT’s, HIV 











 Abdominal pains 
 Muscle aches 
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f. Patient education should be conducted, ensuring patient makes an informed decision to 
take buprenorphine products to manage withdrawal symptoms/OUD. Provider will 
document that this discussion took place.  
 
g. SOS recovery coach (800-864-9040) to be called in while arranging ED induction or 
Home induction- Recovery Coach will offer their services to the patient while patient is 
in the ED.  (If patient declines Recovery Coach services after coach arrives, this does not 
preclude patient from receiving buprenorphine or Rx at discharge.) 
h. Consider other prescribed or recreational substances and interactions as 
withdrawal/comfort meds are prescribed 
i. Consider complicating factors and potential contraindications: 
o Recent methadone or long-acting opioid use (risk for precipitated withdrawal) 
o Unstable alcohol, benzodiazepine or other sedative use 
o Medical, psychiatric, or surgical instability or decompensated liver/lung/heart/kidney 
disease 
o Prisoner- consult with jail medical staff  





1. Buprenorphine products (either buprenorphine (“Subutex” ®) or buprenorphine/naloxone 
a) Please Note:  
• Use with caution in patients requiring opioid analgesics for pain management 
• Do not use in patients who may require surgery in the next seven days 
• IF AFTER CONSULTATION WITH OB, a decision is made to start buprenorphine 
in pregnant patient, buprenorphine without naloxone (Subutex), may be used. 
b) Do not administer buprenorphine until patient objectively demonstrates signs and 
symptoms of opioid withdrawal (COWS score >8) or precipitated withdrawal may occur. 
c) Withdrawal typically begins: 12 hours after last dose of short-acting opioid (heroin, 
oxycodone, Vicodin, etc.) or 24-48 hours after last dose of long-acting opioid 
(methadone) 
d) First dose: 
• Wait until COWS score >8 before giving initial buprenorphine dose 
• Administer buprenorphine SL 4mg or buprenorphine/naloxone SL 4mg/1mg (may 
consider initial dose of 8mg if COWS score >12). 
 
e) Observe for 45-60 minutes and if no adverse reaction, administer second dose of 4mg 
buprenorphine or 4mg/1mg buprenorphine/naloxone. 
 
f) Observe for 60 minutes.  If patient remains in moderate withdrawal (COWS >8), may 
consider adding additional 4mg buprenorphine or 4mg/1mg buprenorphine/naloxone and 
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a) May be given instead of buprenorphine for opioid withdrawal or to supplement treatment 
(not needed if able to bridge to appointment for continued buprenorphine treatment).  
b) Administer 0.1mg every 6 hours PRN signs and symptoms of withdrawal 
c) Do not exceed 0.4mg in 24 hours 
d) Hold any doses if: 
• SBP < 90 or DBP < 50 mm Hg 
• HR < 50  
• Excessive sedation 
• Orthostatic hypotension (drop of 20 mm Hg in SBP or 10 mm Hg in DBP) 
 
3. To augment opioid withdrawal treatment, consider symptom-targeted treatment as below: 
a) Mild-moderate pain management options 
• Acetaminophen 650mg PO every 6 hours PRN mild to moderate pain, not to 
exceed 4000mg in 24 hours in patients with normal hepatic function or 2000mg in 
patients with hepatic disease/cirrhosis 
• Ibuprofen 400mg PO PRN every 6 hours for mild pain, OR 600mg PO PRN every 
6 hours for moderate pain, or 800mg PO every 8 hours PRN for moderate pain, 
not to exceed 2400mg in 24 hours; avoid in patients with renal impairment (eGFR 
< 30 mL/min/1.73m2) 
b) Abdominal cramps 
• Dicyclomine 10mg PO every 6 hours PRN for mild stomach cramps, or 20 mg PO 
every 6 hours for moderate stomach cramps 
c) Diarrhea 
• Loperamide 4mg PO after first loose stool, then 2mg PO each additional loose 
stool, not to exceed 16mg in 24 hours 
d) Nausea 
• Ondansetron 4 mg PO every 8 hours PRN or 2 mg IV every 6 hours PRN Nausea 
or vomiting (CAUTION: Combination of buprenorphine and ondansetron may 
prolong QT interval) OR 
• Promethazine (Phenergan)-25mg PO every 6 hours PRN 
e) Dyspepsia 
• Famotidine 40mg every 8 hours PRN 
f) Muscle cramping 
• Methocarbamol 750mg PO every 6-8 hours PRN muscle cramps 
g) Insomnia 
• Melatonin –over the counter 
o 5mg PO every night before bed for mild insomnia, OR 10mg PO every 
night before bed for moderate insomnia 
• Trazadone –  
o 50mg every night before bed for mild insomnia, OR 100mg PO every 





Buprenorphine X-Waivered providers-  
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• Prior to prescribing buprenorphine, providers should check NH Prescription Drug 
Monitoring Program. 
• Provide short term (2-7 day Rx for buprenorphine/naloxone 8mg/2mg (tabs or films) OR 
buprenorphine SL 8mg tabs, take 2 tabs or films SL one time daily). Write RX as 
follows:  
o Buprenorphine/Naloxone 8mg/2mg Films (interchange with tabs as needed per 
insurance coverage) 
o Instructions: Take 2 films (or tabs) sublingually one time daily. 
o Dispense: 2- 7 day supply (duration can depend on when Doorway is able to 
secure f/u appt for patient) 
 
• If patient was not in withdrawal (COWS <8) then follow Buprenorphine Home 
Induction Guideline for prescription dosing. 
 
Take home Naloxone and Overdose prevention- 
• Ensure all patients are educated on and given intranasal naloxone kit/instructions to take 
home.  
 
Treatment and Harm Reduction Referral:  
• RN or recovery coach will make direct phone call to WDH Doorway (603-740-2253) so 
care coordinators can arrange f/u within 2-7 days for patient with ongoing outpatient 
treatment.  After hours, message to be left with patient contact information and Doorway 
care coordinator will contact patient next business day. Secure fax with patient 
information may also be sent to Doorway at fax 603-609-6691.   
• Options for ongoing care may include the following WDH community buprenorphine 
partners: 
o Addiction Recovery Services- Intensive Outpatient Program 
Office: 603-433-6250 
Fax: 603-433-6350 
1145 Sagamore Ave. Portsmouth, NH 03801 
Cell: 814-515-9896 
Website: arsnh.com  
Email: info@arsnh.com 
o Groups 
40 Winter St., # 204, Rochester, NH 




• Referral to SOS Recovery (603) 841-2350- if patient declined to speak to on-call 
recovery coach during encounter.  
• Also refer to Hand-Up Health Services- (http://nhhrc.org/resources/handup/) ((207) 370-
7187) for syringes/naloxone refills/other harm reduction services in case of continued use 
or return to use.   
• As needed, involve social work services for housing/financial assistance/PCP linkage 











Guideline: ED Buprenorphine/naloxone Home Induction Guideline 
Applies to: Department of Emergency Medicine 
Effective Date: 3/20/19 
Reviewed and Approved 
by: 
Standardization Committee (Approved 2/26/19), P and T 
(Approved 3/20/19) 
Last Revision: 3/20/19 
 
Standards/Definitions:  
The following guideline has been developed to provide guidance initiating treatment with 
buprenorphine/naloxone (Suboxone) for Emergency Department (ED) patients with opioid use 
disorder. The management of opioid use disorder (OUD) is based on individual assessment and 
may vary based on specific clinical presentations. The guideline applies to patients equal to or 
greater than 18 years old and have an opioid use disorder based on meeting at least four of the 
DSM-5 criteria (see Assessment below).  
 
Recommendations in this guideline derived from: 
ASAM Clinical Practice Guideline: https://www.asam.org/docs/default-source/practice-
support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf 




Note: The provision of buprenorphine/naloxone from the ED for at home induction is 





• Possess a DEA DATA X-waiver to prescribe buprenorphine for home induction  
• Check Prescription Drug Monitoring Program (PDMP) to check for prescriptions not 
reported 
 
Patients should NOT: 
• Have acute/chronic pain requiring opioid management  
• Need higher levels of care/admission due to advanced psychiatric illness or poly-
substance use prior to induction 
• Be on methadone maintenance 
 
Assessment: 
a) Medical exam 
b) Identify patients with possible OUD (“How many times in the last year have you used 
heroin, fentanyl or prescription opioids for nonmedical reasons?” Any response more 
than “never” is a positive screen and warrants further assessment.) 
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c) Assess eligibility for ED-initiated buprenorphine by meeting following criteria: 
o Recent regular opioid use (i.e. daily/almost daily use including within last 7 days) 
o Meets DSM-5 criteria for moderate to severe OUD (4 or more criteria) 
o Opioids are often taken in larger amounts or over a longer period of time 
than intended. 
o There is a persistent desire or unsuccessful efforts to cut down or control 
opioid use. 
o A great deal of time is spent in activities necessary to obtain the opioid, 
use the opioid, or recover from its effects. 
o Craving, or a strong desire to use opioids. 
o Recurrent opioid use resulting in failure to fulfill major role obligations at 
work, school or home. 
o Continued opioid use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of opioids. 
o Important social, occupational or recreational activities are given up or 
reduced because of opioid use. 
o Recurrent opioid use in situations in which it is physically hazardous  
o Continued use despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or 
exacerbated by opioids. 
o *Tolerance, as defined by either of the following: (a) a need for markedly 
increased amounts of opioids to achieve intoxication or desired effect (b) 
markedly diminished effect with continued use of the same amount of an 
opioid 
o *Withdrawal, as manifested by either of the following: (a) the 
characteristic opioid withdrawal syndrome (b) the same (or a closely 
related) substance are taken to relieve or avoid withdrawal symptoms 
d) Needs treatment (i.e. not already engaged in formal medication treatment program) 
e) Assess for signs and symptoms of withdrawal 
o Opioid withdrawal symptoms include: 
 
 











 Abdominal pains 
 Muscle aches 
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(https://www.mdcalc.com/cows-score-opiate-withdrawal or see end of this document) to 
determine if patient is in active withdrawal.  If COWS score is >8, consider ED induction (see 
WDH Opioid Withdrawal Guideline).  If COWS<8, patient may be considered for Home 
Induction.   
f) Consider: Urine tox screen, pregnancy test. Lab testing not required but urine tox can 
confirm opioid use and exclude recent methadone if concerned.  Consider LFT’s, HIV 
and Hep screens as these are recommended in early treatment. 
g) Patient education should be conducted, ensuring patient makes an informed decision to 
take buprenorphine products to manage OUD. Provider will document that this 
discussion took place.  
h) SOS recovery coach (800-864-9040) to be called in while arranging Home 
Induction/plan for discharge- Recovery Coach will offer their services to the patient 
while patient is in the ED.  (If patient declines Recovery Coach services after coach 
arrives, this does not preclude patient from receiving buprenorphine or Rx at discharge). 
i) Consider other prescribed or recreational substances and interactions as 
withdrawal/comfort meds are prescribed 
j) Consider complicating factors and potential contraindications: 
o Recent methadone or long-acting opioid use (risk for precipitated 
withdrawal 
o Unstable alcohol, benzodiazepine or other sedative use 
o Medical, psychiatric, or surgical instability or decompensated 
liver/lung/heart/kidney disease 
o Prisoner- consult with jail medical staff  
o Pregnancy (buprenorphine not contraindicated but MUST be managed 
with OB consult. Inpatient induction recommended for gestational 
age >20 weeks.) 
 
Medication orders: 
• For non-pregnant patients without other contraindications, ED Provider will prescribe the 
following RX: 
o Buprenorphine/Naloxone 8mg/2mg Films (interchange with tabs as needed per 
insurance coverage) 
o Instructions: On day 1, take 4mg sublingually experiencing at least 3 withdrawal 
symptoms.  Wait 45 minutes and if still having symptoms, take another 4mg.  
Wait 6 hours and if still having symptoms, take additional 4mg.  On day 2 and 
beyond, take 16mg sublingually one time daily. 
o Dispense: 2- 7 day supply (duration can depend on when Doorway is able to 
secure f/u appt for patient) 
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• Provide patient with detailed handout: “Guide for Patients Beginning Buprenorphine 
Treatment at Home” (See Handout at end of this document. Copies will also be stored in 
ED buprenorphine binder) 
 
 
• If it is decided that a pregnant patient is appropriate for outpatient induction and that 
buprenorphine without naloxone product is to be used, the following RX would be 
provided: 
o Buprenorphine SL tablet 8mg.  
o Instructions: On day 1, take ½ tablet(4mg) when you are experiencing at least 3 
withdrawal symptoms. Wait 45 minutes and if still feeling withdrawal symptoms, 
take ½ tablet.  Wait 6 hours, and if still feeling withdrawal symptoms, take an 
additional ½ tablet.  On day 2, take 2 tablets (total 16 mg buprenorphine) once 
daily.  Repeat this 16 mg dose once daily until follow-up appointment.  (2-7 day 
supply provided, depending on arranged day of follow-up with community 
buprenorphine provider) 
 
o Provide patient with detailed handout: “Guide for Patients Beginning 
Buprenorphine Treatment at Home” (See Handout at end of this document. 




Take home Naloxone and Overdose prevention- 





Treatment and Harm Reduction Referral:  
• RN or recovery coach will make direct phone call to WDH Doorway (603-740-2253) so 
care coordinators can arrange f/u within 2-7 days for patient with ongoing outpatient 
treatment.  After hours, message to be left with patient contact information and Doorway 
care coordinator will contact patient next business day. Secure fax with patient 
information may also be sent to Doorway at fax 603-609-6691.   
• Options for ongoing care may include the following WDH community buprenorphine 
partners: 
o Addiction Recovery Services- Intensive Outpatient Program 
Office: 603-433-6250 
Fax: 603-433-6350 
1145 Sagamore Ave. Portsmouth, NH 03801 
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Cell: 814-515-9896 
Website: arsnh.com  
Email: info@arsnh.com 
o Groups 
40 Winter St., # 204, Rochester, NH 




• Referral to SOS Recovery (603) 841-2350—especially if patient declined to speak to on-
call recovery coach during encounter.  
 
• Also refer to Hand-Up Health Services- (http://nhhrc.org/resources/handup/) ((207) 
370-7187) for syringes/naloxone refills/other harm reduction services in case of 
continued use or return to use.   
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Appendix F 
Buprenorphine waiver trainings: 













ED Buprenorphine Binder documents: 
WDH approved ED guidelines- 
a. Opioid Withdrawal- 
https://docs.google.com/document/d/1pjcDf69gOeSdgRU8zqUnreKkH8eXeuZdGRFin1t
HcNo/edit?usp=sharing  
b. Home Induction- 
https://docs.google.com/document/d/1BQs7G8GxkwRujbyE670mTO6FwwwqSMF6ZET
QdT04JMg/edit?usp=sharing  
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NIDA ED Buprenorphine Academic Detailing brochure- 
https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/edbuprenorphinehandout.pdf 
 
NIDA Home Initiation of Buprenorphine Patient Handout- 
https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/home_buprenorphine_initiation.pdf 
 
NIDA ED Buprenorphine Initiation Algorithm- 
https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/algorithm.pdf 
 
Buprenorphine: A Guide for Nurses- 
https://www.naabt.org/documents/TAP30.pdf  
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Appendix I 
UNH Quality Improvement Approval Letter 
 
